Showing results (81-90 of 149) with videos related to

Sort By:
Pageof 15
The Journal of Investigative Dermatology|March 1, 1996
Human dermal fibroblasts produce nitric oxide and express both constitutive and inducible nitric oxide synthase isoformsR Wang, A Ghahary, Y J Shen, et al.
Wound Repair and Regeneration : Official Publication of the Wound Healing Society [And] the European Tissue Repair Society|October 20, 1998
Effect of interferon-alpha2b on guinea pig wound closure and the expression of cytoskeletal proteins in vivoB Nedelec, C M Dodd, P G Scott, et al.
The Journal of Hand Surgery|June 5, 1999
The effect of interferon-alpha2b on an in vitro model Dupuytren's contractureJ L Sanders, C Dodd, A Ghahary, et al.
The Journal of Laboratory and Clinical Medicine|November 1, 1995
The effect of interferon alpha 2b on the expression of cytoskeletal proteins in an in vitro model of wound contractionB Nedelec, Y J Shen, A Ghahary, et al.
The Journal of Investigative Dermatology|January 1, 1995
Alteration in cell morphology triggers transforming growth factor-beta 1, collagenase, and tissue inhibitor of metalloproteinases-I expression in normal and hypertrophic scar fibroblastsM Varedi, E E Tredget, P G Scott, et al.
Molecular and Cellular Biochemistry|July 5, 1995
Enhanced expression of mRNA for insulin-like growth factor-1 in post-burn hypertrophic scar tissue and its fibrogenic role by dermal fibroblastsA Ghahary, Y J Shen, B Nedelec, et al.
The Journal of Investigative Dermatology|May 14, 1998
Genetically modified dermal keratinocytes express high levels of transforming growth factor-beta1A Ghahary, E E Tredget, L J Chang, et al.
The Journal of Investigative Dermatology|April 1, 1997
Nitric oxide synthase expression and nitric oxide production are reduced in hypertrophic scar tissue and fibroblastsR Wang, A Ghahary, Y J Shen, et al.
The Annals of Pharmacotherapy|April 1, 1993
Prospective surveillance of imipenem/cilastatin use and associated seizures using a hospital information systemS L Pestotnik, D C Classen, R S Evans, et al.
JAMA|January 22, 1997
Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortalityD C Classen, S L Pestotnik, R S Evans, et al.
Pageof 15